Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are suspected or known to have a condition called Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC), which may be indicated by having skin tumours called leiomyomas along with kidney cancer; or skin leiomyomas along with uterine (womb) leiomyomas (fibroids); or multiple skin leiomyomas; or kidney cancer along with uterine leiomyomas; or a type of kidney tumour that is consistent with HLRCC (such as Collecting Duct or Papillary Type II tumours).
- People who are a blood relative of someone who has been diagnosed with, or is suspected to have, HLRCC.
- People who are aged 2 years or older.
- All participants (and parents or guardians, for those under 18 years old) must sign a consent form showing they understand what the study involves and its potential risks before taking part.
Who may not be able to join:
- No specific exclusion criteria have been listed for this trial (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: W. Marston Linehan, M.D., National Cancer Institute (NCI)
Phone: (240) 760-6247
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine the incidence and characteristics of HLRCC-associated fumarate hydratase gene mutations.; Determine the clinical manifestations of HLRCC; Determine if other genes cause HLRCC.; Determine genotype/phenotype correlations.; Define the types and characteristics (including patterns of growth) of renal cancer associated with HLRCC.; Define the risk of developing renal cancer, cutaneous leiomyoma and uterine leiomyoma in this hereditary cancer syndrome.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.